OSTEOSCAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OSTEOSCAN (OSTEOSCAN).
Bisphosphonate that inhibits bone resorption by binding to hydroxyapatite and inhibiting osteoclast activity.
| Metabolism | Not metabolized; excreted unchanged by the kidneys. |
| Excretion | Renal: 100% (as unchanged drug within 24 hours). Biliary/fecal: negligible. |
| Half-life | Terminal elimination half-life: 2.5 hours (range 1.5–4.0 hours) in patients with normal renal function; prolonged in renal impairment. |
| Protein binding | 25% (primarily to albumin). |
| Volume of Distribution | 0.3 L/kg (indicating distribution primarily into extracellular fluid and bone). |
| Bioavailability | Intravenous: 100%. Not administered orally. |
| Onset of Action | Intravenous: Within 2 hours (peak skeletal uptake). |
| Duration of Action | Effective skeletal imaging can be performed 2–5 hours post-injection; maximal bone uptake at 2–4 hours. |
20 mCi (740 MBq) intravenously as a single dose for bone imaging
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment recommended; however, caution in severe renal impairment (GFR <30 mL/min) due to reduced clearance and potential increased radiation exposure |
| Liver impairment | No dose adjustment required for hepatic impairment; not metabolized by liver |
| Pediatric use | 0.2-0.3 mCi/kg (7.4-11.1 MBq/kg) intravenously, minimum dose 1 mCi (37 MBq) |
| Geriatric use | No specific dose adjustment; use lowest effective dose to minimize radiation exposure; consider renal function in elderly |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OSTEOSCAN (OSTEOSCAN).
| Breastfeeding | Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants. Discontinue nursing or drug. |
| Teratogenic Risk | Fetal risk exists primarily due to radiation exposure. First trimester exposure associated with potential teratogenicity; risk of fetal harm outweighs benefits. Use contraindicated in pregnancy. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to technetium Tc-99m medronate or any component of the formulation"]
| Precautions | ["Renal impairment may delay clearance and increase radiation exposure","Hydration recommended before administration","Not for intrathecal use"] |
Loading safety data…
| Monitor maternal vital signs and radiation exposure. Assess fetal radiation dose if inadvertent exposure occurs. No routine fetal monitoring indicated. |
| Fertility Effects | No specific data on fertility impairment. Radiation exposure may theoretically affect gonadal function; however, clinical significance unknown. |